FibroGen Inc (FGEN)
0.3643
+0.03
(+10.19%)
USD |
NASDAQ |
Nov 14, 12:22
FibroGen Cash from Investing (Quarterly): 72.24M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 72.24M |
| March 31, 2024 | 51.28M |
| December 31, 2023 | 10.24M |
| September 30, 2023 | 54.22M |
| June 30, 2023 | -14.28M |
| March 31, 2023 | 103.48M |
| December 31, 2022 | 1.093M |
| September 30, 2022 | 44.78M |
| June 30, 2022 | 17.30M |
| March 31, 2022 | 25.94M |
| December 31, 2021 | -50.57M |
| September 30, 2021 | -122.15M |
| June 30, 2021 | -57.53M |
| March 31, 2021 | -196.72M |
| December 31, 2020 | 143.77M |
| September 30, 2020 | 98.86M |
| June 30, 2020 | 153.86M |
| March 31, 2020 | 56.01M |
| December 31, 2019 | -25.03M |
| September 30, 2019 | 152.77M |
| June 30, 2019 | 18.77M |
| Date | Value |
|---|---|
| March 31, 2019 | -26.49M |
| December 31, 2018 | -462.86M |
| September 30, 2018 | -89.20M |
| June 30, 2018 | 14.64M |
| March 31, 2018 | 15.30M |
| December 31, 2017 | 20.00M |
| September 30, 2017 | 9.541M |
| June 30, 2017 | 16.92M |
| March 31, 2017 | 23.41M |
| December 31, 2016 | -9.115M |
| September 30, 2016 | 8.585M |
| June 30, 2016 | 2.093M |
| March 31, 2016 | 5.059M |
| December 31, 2015 | -11.71M |
| September 30, 2015 | -0.208M |
| June 30, 2015 | 1.494M |
| March 31, 2015 | 4.552M |
| December 31, 2014 | -140.29M |
| September 30, 2014 | 3.41M |
| June 30, 2014 | 17.38M |
| March 31, 2014 | 12.22M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-196.72M
Minimum
Mar 2021
153.86M
Maximum
Jun 2020
19.30M
Average
25.94M
Median
Mar 2022
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Arbutus Biopharma Corp | -11.99M |
| GlycoMimetics Inc | -0.0025M |
| Cidara Therapeutics Inc | 0.00 |
| Cue Biopharma Inc | -0.01M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -39.87M |
| Cash from Financing (Quarterly) | 0.032M |
| Free Cash Flow | -202.99M |
| Free Cash Flow Per Share (Quarterly) | -0.3995 |
| Free Cash Flow to Equity (Quarterly) | -40.15M |
| Free Cash Flow to Firm (Quarterly) | -33.91M |
| Free Cash Flow Yield | -563.5% |